PD-1 inhibitor benefit possible even after discontinuation February 21, 2017By Leah LawrencePersistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
In this issue
Antibiotics may negatively impact immunotherapy outcomes February 21, 2017By Leah LawrenceAdministration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis. Novel bladder Ca agent shows promise in phase II trial February 21, 2017By Lisette HiltonAn investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported. Rheumatologic side effects possible with immunotherapies February 21, 2017By Keith LoriaCancer patients taking certain immunotherapy drugs may be more susceptible to developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a recent study. Cyclosporine shows efficacy in refractory IC patientsOral cyclosporine can offer a safe and effective treatment option for refractory interstitial, even in patients who have been on chronic narcotic medications and particularly in those with Hunner’s lesions, according to the findings of a study presented by Cleveland Clinic urologists at the 2016 AUA annual meeting in San Diego. VA rule on APRNs places veterans’ health first“The evidence is clear: Not only can APRNs practice independently, they can do so effectively and without sacrificing quality of care,” writes SUNA President Gwendolyn Hooper, PhD, APRN.